Skip to main content

Developing Autologous processes: starting with the end in mind

25 Jun 2024
Salon D
  • Developing robust processes in early phase with commercial already in mind
  • Removing roadblocks to scalability proactively vs. reactively
  • Avoiding costly choices in end to end manufacturing process development – starting with the end in mind
  • Plan proactively where to invest your time and efforts
Industry Expert
Andrew Snowden, Senior Director, Allogeneic & Autologous Cell Therapy Process Development - Johnson & Johnson